News & Updates

Therapeutic-dose anticoagulation has contributed to a decrease in the likelihood of organ support or death among noncritically ill hospitalized patients with COVID-19. Such experience shows how quick and rigorous approaches, when aligned, can promptly translate evidence into practice, suggests a study.

Three antithrombotic medications (aspirin, clopidogrel, and rivaroxaban) demonstrate noninferiority to metoprolol for responder rate (RR) in patients with migraine and patent foramen ovale (PFO), a study has shown. Rivaroxaban also delivers the highest RR without increasing major bleeding events.